Occidiofungin is Sano's lead compound and is a first-in-class compound which utilizes a novel mechanism of action. Originally discovered in 2009, it exhibits potent activity against an array of drug-resistant pathogens. Given its spectrum of activity, it is under investigation as a cure for recurrent vulvovaginal yeast infections, systemic fungal infections, and for dermal and mucosal applications.
What is Occidiofungin?
Occidiofungin is a natural product produced by our proprietary bacterial strain. After being cultivated at our facilities with patented technology, occidiofungin is extracted and purified. The compound kills fungi and restricts growth by disrupting actin filaments, resulting in apoptotic cell death.
Treatment for Chronic Yeast Infections
Occidiofungin is being studied for the treatment of recurrent vulvovaginal candidiasis (RVVC) in adult women. Currently, our drug has completed nonclinical studies which indicate safety and efficacy in animals, and the INDA for Phase I clinical trials has been approved by the FDAs in humans.
Treatment for Other Severe Fungal Infections
Increasingly, drug resistant fungi present a threat to patients, particularly those that are immunocompromised or immunodeficient as a result of heredity or due to chemotherapy. Occidiofungin will be investigated as a systemic treatment which could offer solutions to such infections.
Occidiofungin for Other Fungal Indications
Occidiofungin holds great promise as a treatment for other fungal infections. Its use to teat dermal candidiasis (DC) and oral candidiasis (OC) are being investigated. Occidiofungin's bioactivity properties may provide a more effective treatment option with less toxicity and shorter duration of treatment. Further, Candida auris is a serious health concern and occidiofungin holds great promise as an effective therapeutic.